CARDERA (n=467) | TACIT (n=205) | |||||
---|---|---|---|---|---|---|
Characteristic | Placebo (n=236) | Steroids (n=231) | p Value | cDMARDs (n=104) | TNFi (n=101) | p Value |
Demographic | ||||||
Number (%) female | 157 (67) | 166 (72) | 0.251 | 73 (70) | 79 (78) | 0.249 |
Age (years) | 53.8 (13.6) | 54.5 (11.5) | 0.567 | 58.0 (12.9) | 56.7 (11.0) | 0.459 |
RA specific | ||||||
Disease duration (years) | 0.3 (0.4) | 0.4 (0.5) | 0.082 | 7.3 (8.4) | 9.2 (9.2) | 0.126 |
DAS28 | 5.84 (1.27) | 5.71 (1.30) | 0.266 | 6.21 (0.92) | 6.30 (0.81) | 0.461 |
SJC | 10.0 (6.5) | 9.7 (6.1) | 0.577 | 10.5 (6.1) | 10.8 (6.7) | 0.753 |
ESR | 40.9 (28.9) | 40.8 (29.6) | 0.979 | 33.1 (26.1) | 30.1 (22.8) | 0.379 |
TJC | 12.3 (7.4) | 11.3 (7.8) | 0.130 | 16.4 (7.1) | 17.5 (6.7) | 0.259 |
PtGA | 54.3 (26.7) | 55.6 (26.0) | 0.582 | 68.1 (19.7) | 68.2 (21.3) | 0.988 |
HAQ | 1.59 (0.68) | 1.59 (0.69) | 0.984 | 1.80 (0.59) | 1.90 (0.67) | 0.251 |
HRQoL | ||||||
PF | 33.6 (24.5) | 34.3 (24.0) | 0.754 | 30.1 (22.6) | 24.6 (20.9) | 0.067 |
RP | 14.4 (29.5) | 17.9 (32.8) | 0.233 | 14.9 (30.1) | 12.4 (26.1) | 0.521 |
BP | 33.2 (21.0) | 34.4 (21.4) | 0.541 | 28.1 (16.3) | 26.3 (17.8) | 0.435 |
GH | 44.4 (21.1) | 46.4 (19.9) | 0.305 | 35.8 (18.2) | 31.4 (16.8) | 0.074 |
VT | 31.2 (20.3) | 34.7 (20.7) | 0.063 | 30.3 (21.4) | 26.6 (19.0) | 0.185 |
SF | 48.3 (31.2) | 54.4 (29.7) | 0.030 | 50.2 (25.2) | 42.1 (25.3) | 0.022 |
RE | 38.3 (43.7) | 46.5 (44.9) | 0.046 | 43.9 (44.9) | 35.3 (44.9) | 0.172 |
MH | 59.5 (20.0) | 61.6 (19.0) | 0.252 | 61.9 (20.2) | 58.8 (23.1) | 0.305 |
PCS | 29.6 (8.5) | 29.6 (9.5) | 0.969 | 26.5 (7.5) | 25.5 (7.8) | 0.356 |
MCS | 38.3 (15.2) | 41.3 (14.3) | 0.025 | 40.8 (14.8) | 37.6 (14.6) | 0.120 |
Data given as mean (SD) unless otherwise stated; p values for continuous and categorical variables derived from t-tests and χ2 tests, respectively.
BP, bodily pain; cDMARDs, combination disease-modifying antirheumatic drugs; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; GH, general health; HRQoL, health-related quality of life; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; PtGA, patient global assessment of disease activity; RA, rheumatoid arthritis; RE, role emotional; RP, role physical; SF, social functioning; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor-α inhibitor; VT, vitality.